People: Osiris Therapeutics Inc (OSIR.OQ)
Dr. Lode Debrabandere, Ph.D., is President, Chief Executive Officer, Director of Osiris Therapeutics, Inc. Dr. Debrabandere has over 20 years of experience leading R&D, sales and marketing activities in the pharmaceutical and biotechnology industries. In 2006, he joined Osiris as Vice President and General Manager of the Therapeutics Business Unit and was responsible for the development of Prochymal(R) (remestemcel-L), the world's first approved stem cell drug for graft versus host disease. In 2012, he was promoted to Chief Operating Officer and assumed responsibility for all commercial activities of the company. Prior to joining Osiris, Dr. Debrabandere served as Vice President of Global Marketing at Bristol Myers Squibb where he led the Neuroscience Business Unit and was the Global Brand Leader for Abilify(TM). He joined BMS from UCB Pharmaceuticals, Inc., where he led the Clinical Development and Marketing Operations focusing on the areas of allergy/respiratory (Zyrtec(TM)) and neurology (Keppra(TM)).
|Total Annual Compensation, USD||Long-Term Incentive Plans, USD||All Other, USD||Fiscal Year Total, USD|